THE RIGHT THERAPY MATTERS
HAE ATTACKS MAY IMPACT YOUR PATIENTS MORE THAN YOU THINK
86% of patients said that 3 in 4 untreated or inadequately controlled attacks were severe enough to negatively impact quality of life.1
97% of patients agree nothing could be more convenient than a medication that allows them to live attack free.2
* These findings are the result of an online survey conducted by The Harris Poll, sponsored by CSL Behring LLC, involving 100 US adults aged 18+ who have been diagnosed by a healthcare professional with hereditary angioedema (HAE) ("people living with HAE") and 150 licensed allergists/immunologists in the US who have treated/managed at least 2 HAE patients in the past 12 months ("physicians").
BUILD AND MAINTAIN STEADY‑STATE C1‑INH FUNCTIONAL LEVELS
![image showing increase c1-ing levels and decreased risk for attacks](/common/images/hcp/img-function-vs-risk.png)
HAEGARDA replaces missing or dysfunctional C1‑INH with functional C1‑INH, which regulates the normal production of bradykinin
- The root cause of HAE is deficient or dysfunctional C1-INH
- Functional C1-INH levels ≥40% of normal are proposed to reduce the risk of HAE attacks3
- Steady-state C1-INH functional activity is expected within 3 to 4 doses4
What made me try HAEGARDA? It’s the same protein my body is lacking.
-Zahra, HAEGARDA Advocate
C1-INH=C1 inhibitor.
HAE=hereditary angioedema.
The 2021 World Allergy Organization Guidelines recommend use of C1 esterase inhibitors for first-line, long-term prophylaxis.6
The right therapy matters to get to steady state quickly
- Quick acting: steady-state C1‑INH functional levels achieved in approximately the first 2 weeks†
- Subcutaneous C1-INH builds and maintains steady-state C1‑INH functional activity3-5‡
Administered subcutaneously, HAEGARDA 60 IU/kg maintained steady-state C1‑INH functional levels above 40%3-5
† Steady state is expected within 3 to 4 doses.
‡ The plasma levels of C1-INH functional activity were evaluated in patients with type 1 or type 2 HAE in a Phase 3, placebo-controlled, crossover study. Patients received twice-weekly subcutaneous injections of HAEGARDA 40 IU/kg or 60 IU/kg for 16 weeks. The model-derived outcome is the steady-state C1-INH functional activity vs time.4
What makes HAEGARDA different?
HAEGARDA is the HAE product that reduced HAE attacks by 95%.‡
‡ Median reduction in the number of attacks with HAEGARDA 60 IU/kg vs placebo.
WORLD ALLERGY ORGANIZATION (WAO) GUIDELINES RECOMMENDATIONS AND TREATMENT GOALS6
C1‑INH has been used for 35 years and is the WAO-recommended first-line therapy
- The WAO recommends C1‑INH as first-line preventive therapy for HAE for long-term prophylaxis6
- C1‑INH is the preferred therapy for pregnant or breastfeeding HAE patients6
On‑demand treatment goals§
- Shorter time to resolution of symptoms
- Shorter total attack duration regardless of attack severity
§ Short-term or preprocedural prophylaxis can also be administered before an event that may trigger an HAE attack (eg, medical or invasive dental procedure).
Long-term prophylaxis (LTP) treatment goals
- Achieve full control of disease burden
- Attempt to minimize treatment burden and side effects
See on-demand treatment of acute HAE attacks
EXPLORE ON-DEMANDWorld Allergy Organization/European Academy of Allergy and Clinical Immunology guidelines on prophylaxis
"We recommend that HAE patients are evaluated for long-term prophylaxis at every visit. Disease burden and patient preference should be taken into consideration. Evidence Grade D; strength of recommendation strong, 96% agreement."